Day One Biopharma Files 8-K

Ticker: DAWN · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1845337

Sentiment: neutral

Topics: corporate-info, listing

Related Tickers: DAWN

TL;DR

DAY ONE BIOPHARMACEUTICALS (DAWN) filed an 8-K updating office address and confirming Nasdaq listing.

AI Summary

On June 12, 2024, Day One Biopharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California, 94005. The company's common stock trades on the Nasdaq Global Select Market under the ticker symbol DAWN.

Why It Matters

This filing provides an update on the company's corporate information, including its principal executive office location and stock exchange listing.

Risk Assessment

Risk Level: low — This is a routine corporate filing providing basic company information and does not contain material financial or operational news.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about the registrant, Day One Biopharmaceuticals, Inc., including its principal executive offices and stock exchange listing.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 12, 2024.

Where are Day One Biopharmaceuticals, Inc.'s principal executive offices located?

Day One Biopharmaceuticals, Inc.'s principal executive offices are located at 2000 Sierra Point Parkway, Suite 501, Brisbane, California, 94005.

On which stock exchange is Day One Biopharmaceuticals, Inc. common stock traded?

Day One Biopharmaceuticals, Inc. common stock is traded on the Nasdaq Global Select Market.

What is the trading symbol for Day One Biopharmaceuticals, Inc. common stock?

The trading symbol for Day One Biopharmaceuticals, Inc. common stock is DAWN.

Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-12 08:07:14

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DAY ONE BIOPHARMACEUTICALS, INC. Date: June 12, 2024 By: /s/ Charles N. York II, M.B.A. Charles N. York II, M.B.A. Chief Operating Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing